HomeCompareSZIHF vs PFE

SZIHF vs PFE: Dividend Comparison 2026

SZIHF yields 8.52% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $28.4K in total portfolio value· pulled ahead in Year 9
10 years
SZIHF
SZIHF
● Live price
8.52%
Share price
$0.90
Annual div
$0.08
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.2K
Annual income
$0.90
Full SZIHF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SZIHF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZIHFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZIHF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZIHF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZIHF
Annual income on $10K today (after 15% tax)
$724.21/yr
After 10yr DRIP, annual income (after tax)
$0.77/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZIHF + PFE for your $10,000?

SZIHF: 50%PFE: 50%
100% PFE50/50100% SZIHF
Portfolio after 10yr
$35.4K
Annual income
$13,129.81/yr
Blended yield
37.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SZIHF
No analyst data
Altman Z
0.5
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZIHF buys
0
PFE buys
0
No recent congressional trades found for SZIHF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZIHFPFE
Forward yield8.52%6.13%
Annual dividend / share$0.08$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$21.2K$49.6K
Annual income after 10y$0.90$26,258.71
Total dividends collected$873.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SZIHF vs PFE ($10,000, DRIP)

YearSZIHF PortfolioSZIHF Income/yrPFE PortfolioPFE Income/yrGap
1$11,126$426.01$9,153$693.39+$2.0KSZIHF
2$12,126$221.48$8,593$849.25+$3.5KSZIHF
3$13,088$112.80$8,336$1,066.78+$4.8KSZIHF
4$14,061$56.89$8,437$1,384.80+$5.6KSZIHF
5$15,074$28.56$9,013$1,875.40+$6.1KSZIHF
6$16,143$14.31$10,306$2,680.72+$5.8KSZIHF
7$17,281$7.16$12,820$4,101.38+$4.5KSZIHF
8$18,494$3.58$17,673$6,826.70+$821.00SZIHF
9← crossover$19,790$1.79$27,543$12,591.86$7.8KPFE
10$21,176$0.90$49,560$26,258.71$28.4KPFE

SZIHF vs PFE: Complete Analysis 2026

SZIHFStock

Shenzhen International Holdings Limited, an investment holding company, invests in, constructs, and operates logistic infrastructure facilities primarily in the People's Republic of China. It operates through two segments, Toll roads and General Environmental Protection Business, and Logistic Business. The Toll roads and General Environmental Protection Business segment develops, operates, and manages toll highways. This segment also engages in the sale of wind turbine equipment; kitchen waste disposal projects construction; and operation and sale of wind power stations. The company's Logistic Business segment constructs, operates, and manages logistics parks and centers, and integrated logistics hubs; and provides third-party logistics services, logistic information services, and financial services; port and related services; and logistic park transformation and upgrading services. It also operates two general bulk cargo terminals and depots in Nanjing Xiba Port that provides various services, such as loading and unloading, lightering, train loading and unloading, and warehousing. In addition, the company provides electronic information exchange, transmission, and value-added information sharing services; supply chain management services; project investment and enterprise management consulting services; and real estate development and investment management services, as well as operates Longda and Shenzhen Expressway in Shenzhen. Further, it offers logistics and transportation ancillary services, and cargo transportation and warehousing services. Additionally, it provides technical development, sales, maintenance, and technology service of computer hardware, software, and network systems; and monetary and financial leasing, property leasing and management, freight forwarding, and other services. The company is headquartered in Tsimshatsui East, Hong Kong.

Full SZIHF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SZIHF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZIHF vs SCHDSZIHF vs JEPISZIHF vs OSZIHF vs KOSZIHF vs MAINSZIHF vs JNJSZIHF vs MRKSZIHF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.